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significant differences between Klotho groups 2 and 3, and 
the HOMA-IR obtained showed that group 1 (<268) had 
greater odds of HOMA-IR ≥2 when compared with group 
3 (>440), ORa = 21.59, p = 0.017.
Conclusions Our results showed that Klotho levels are 
influenced by FGF23, vitamin D and insulin resistance. 
This suggests that Klotho levels might be affected by renal 
function as well as having a relevant role on insulin metab-
olism and ACR homeostasis.
Keywords Klotho · Chronic kidney disease · Diabetes · 
Mineral metabolism
Introduction
Klotho is a protein expressed in several organs and tissues, 
with greater predominance in the kidney and brain. It has 
been implicated in multiple organic processes, being able 
to regulate growth factors signaling pathways, ion channels 
and transporters [1].
Klotho plays a particularly relevant role within the bone-
kidney endocrine axis. In association FGF-23, it mediates 
the phosphate excretion and homeostasis through the inhi-
bition of 1.25(OH)2 vitamin D3 synthesis and the induction 
of phosphaturia [2].
Recently, increasing evidence links Klotho levels 
with chronic kidney disease (CKD), as basic and clinical 
research have shown the link between Klotho deficiency 
and CKD [3–5] stages. Moreover, Klotho also seems to 
play a renoprotective role through its anti-oxidation proper-
ties: protection of vasculature, promotion of vascularization 
and inhibition of fibrinogenesis [6]. Therefore, it appears 
reasonable to consider Klotho as a potential surrogate 
Abstract 
Purpose The present study aimed at evaluating the rela-
tionship between Klotho levels and insulin resistance 
and albumin-to-creatinine ratio (ACR) in type 2 diabetic 
patients with CKD.
Methods We conducted an observational, cross-sectional 
study in our outpatient diabetic nephropathy clinic from 
2014 to 2016, enrolling a total of 107 type 2 diabetic 
patients with stage 2–3 CKD, with a mean age of 59 years. 
Several clinical and laboratorial parameters were evalu-
ated, including those related to mineral and carbohydrate 
metabolism.
Results The mean eGFR at baseline was 53.2 mL/min, 
and the mean levels of ACR and Klotho were 181.9 µg/mg 
and 331.1 pg/m, respectively. In the simple linear regres-
sion model, Klotho levels were correlated with age, phos-
phorus, PTH, ACR, HOMA, IL-6, FGF-23, OxLDL, eGFR 
and vitamin D levels. Applying a multivariate linear regres-
sion model, only the ACR, HOMA-IR, FGF-23 and vita-
min D independently influenced the Klotho levels. In the 
generalized linear model, only the Klotho groups were sta-
tistically significant as independent variable (p = 0.007). 
The results show that the group 1 (<268) compared with 
group 3 (>440) had higher odds in the higher ACR (≥181), 
ORa = 3.429, p = 0.014. There were no statistically 
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biomarker and target for early intervention and treatment of 
CKD.
Despite this, the association between Klotho and CKD is 
still far from being fully understood, as some studies have 
arrived at divergent conclusions [7, 8]. The discrepancy of 
results may well be explained by the multifactorial patho-
physiology of CKD, especially in patients with comorbidi-
ties, such as diabetics.
In this group, some studies argued that Klotho levels 
may be able to mediate insulin metabolism through the 
inhibition of intracellular insulin and IGF1 signaling [9], as 
well as to enhance glucose-induced insulin secretion [10].
Furthermore, different studies have speculated that 
Klotho levels might also be correlated with the albumin-to-
creatinine ratio (ACR) both by direct [11, 12] and indirect 
mechanisms, with low Klotho levels being associated with 
proteinuria.
In the present study, our objective was to evaluate the 
relationship between Klotho levels and insulin resistance 
and ACR. We intended to understand Klotho’s role in insu-
lin resistance, as well as to examine whether it played a 




An observational, cross-sectional study was conducted in 
our outpatient diabetic nephropathy clinic from 2014 to 
2016, enrolling a total of 107 type 2 diabetic patients with 
stage 2–3 CKD. The diabetes classification was based on 
the American Diabetes Association guidelines [13].
The exclusion criteria were: age > 75 years, previous 
CVD (defined as history of one or more of the following: 
non-fatal myocardial infarction, (stable or unstable) angina 
pectoris, stroke or transient ischemic attacks, peripheral 
vascular disease or congestive heart failure); uncontrolled 
hypertension (BP ≥ 140/90 mmHg), albumin-to-creatinine 
ratio (ACR) >500, estimated glomerular filtration rate 
(eGFR) ≤29 or >90 mL/min, type 1 diabetes, known neo-
plastic or infectious diseases, non-diabetic renal disease 
(patients without previous history of diabetes, with diagno-
sis of glomerulopathies associated with other pathologies 
like systemic diseases, IgA nephropathy, kidney disease of 
unknown ethology, chronic interstitial nephritis, vasculi-
tis, component complement 3 pathologies or renal heredi-
tary diseases. Patients with parathyroid hormone (PTH) 
≥350 pg/mL were excluded to avoid bias from anti-hyper-
parathyroidism medication that can affect Klotho and FGF-
23 levels. The same happened with patients with phos-
phorus >5.5 and the phosphorus-chelating agents that can 
affect the Klotho-FGF-23 axis. Patients undergoing therapy 
with vitamin D and vitamin D receptor activators and phos-
phate binders were also excluded.
Blood measurements
Fasting samples were drawn from all subjects, and plasma 
was frozen at −80 °C in order to measure eGFR, phospho-
rus (P), calcium (Ca), PTH, ACR, insulin resistance degree, 
interleukin-6 (IL-6), fibroblast growth factor-23 (FGF 23), 
1.25(OH)2D3 (vitamin D), oxidized low density lipoprotein 
(oxLDL) and soluble α-Klotho (Klotho). Serum levels of 
FGF-23 were quantified using an enzyme-linked immuno-
sorbent assay, Human FGF-23 (C-Term) ELISA kit (Cat. 
#60-6100 Immunotopics Inc, San Clemente, CA, USA). 
Serum levels of vitamin D were determined with the help 
of a radioimmunoassay (IDS, Boldon, UK). Phosphorus 
and calcium were assayed by the ARCHITECTc Systems 
and the AEROSET System (Abbott Diagnostics Division, 
Abbott Laboratories Abbott Park, IL). IL-6 and oxLDL 
determination was done with a sandwich enzyme-linked 
immunoassay (ELISA) kit (eBioscience, San Diego, Cali-
fornia). PTH levels were measured using an electrochemi-
luminescent immunoassay (ECLIA). PTH concentrations 
were measured on an Immulite 2000 Intact PTH assay 
(Cat. #L2KPP2, Siemens Medical Solutions Diagnostics, 
Los Angeles, CA, USA). Soluble α-Klotho serum levels 
were determined by enzyme-linked immunosorbent assay 
using the “Human soluble α-Klotho ELISA kit” (Code 
no-27998, IBL—Immuno-Biological Laboratories Co., 
Ltd, Gunma, Japan), according to manufacturer’s instruc-
tions and adapted to Triturusmicroplate automatic sys-
tem (Grifols S.A., Barcelona, Spain). The degree of insu-
lin resistance was estimated using the homeostasis model 
assessment (HOMA-IR) described by Matthews et al. [14]. 
Serum creatinine was assayed by the enzymatic method, 
using the  ARCHITECT® device (Abbott Diagnostics Divi-
sion, Abbott Laboratories Abbott Park, IL). We estimated 
the GFR according to the Chronic Kidney Disease Epide-
miology Collaboration (CKD-EPI) Equation [15].
Statistical analysis
Descriptive quantitative data were presented as mean and 
standard deviation. Simple linear regressions were used to 
investigate possible correlations between these variables 
and Klotho. Only the variables with a statistically signifi-
cant relationship were introduced in a multiple regression 
model. The generalized linear model (GLM) for binary 
dependent variables was used (binomial distribution) with 
a logistic link function. The exponentials of the model 
parameters were the adjusted odds ratio (ORa) to other var-
iables of the model. The test was used to determine whether 
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Klotho was an important predictive factor in the determina-
tion of the albumin-to-creatinine event and the resistance to 
insulin. Prior to conducting the GLM, the 25th, 50th and 
75th percentiles of serum Klotho level in the current study 
population were determined. The subjects were categorized 
as follows: group 1 (Klotho < 268), group 2 (Klotho: 268–
440) and group 3 (Klotho > 440).
The null hypothesis was rejected below the level of 5%. 
Statistical analysis was performed using SPSS (version 
17.0; SPSS, Chicago, IL).
Institutional Ethics Committee approval (reference 
207/2010) was obtained for this study.
Results
One hundred and seven (107) consenting patients with 
stage 2–3 CKD were included in the study after confirming 
they did not meet any of the exclusion criteria.
The mean age was 59 ± 8.6 [range 41–72] years, and the 
mean Klotho level was 331.10 ± 171.06 [range 70–663 pg/
mL]. The demographic and clinical parameters are pre-
sented in Table 1.
Simple linear regression (Table 2) demonstrated 
that Klotho levels were inversely correlated with age 
(r = −0.232, p = 0.016), phosphorus (r = −0.381, 
p < 0.001), PTH (r = −0.606, p < 0.001), ACR 
(r = −0.336, p < 0.001), HOMA-IR (r = −0.482, 
p < 0.001), IL-6 (r = −0.571, p < 0.001), FGF-23 
(r = −0.695, p < 0.001), OxLDL (r = −0.598, p < 0.001) 
and directly correlated with eGFR (r = 0.234, p = 0.021) 
and vitamin D (r = 0.661, p < 0.001) levels.
Applying the multivariate linear regression (Table 3), 
only the ACR (r = −0.636 p = 0.036), HOMA 
(r = −0.322, p = 0.018), FGF-23 (r = −0.668 p < 0.001) 
and vitamin D (r = 8.465 p = 0.010) independently influ-
enced Klotho levels.
In the generalized linear model (GLM), only the 
Klotho groups were statistically significant as independ-
ent variable (p = 0.007). The results show that group 1 
(<268) compared to group 3 (>440) had higher odds in 
the higher ACR (≥181), ORa = 3.429, p = 0.014. Group 
2 had no statistical significant difference compared to 
group 3. The optimized model as function of Klotho 
groups, clearance values, age, phosphorus, PTH, IL6, 
vitamin D, OxLDL and FGF-23 allowed for a final and 
statistical significant model (p < 0.001) which included 
Klotho groups and vitamin D variables. The area under 
the ROC curve for this optimized model was 0.772 
Table 1  Patients demographic and clinical characteristics at baseline
Values are presented as mean ± standard deviation
Characteristics Values
Number of patients (n) 107
Gender (f/m) 40/67
Age (years) 59.00 ± 8.57
Hb (g/dL) 12.97 ± 1.83
Albumin (g/dL) 4.27 ± 0.48
eGFR (mL/min) 53.20 ± 10.15
ACR (µg/mg) 181.89 ± 123.83
Phosphorus (mg/dL) 3.99 ± 0.85
PTH (pg/mL) 113.11 ± 74.65
Calcium (mg/dL) 9.43 ± 0.92
FGF-23 (RU/mL) 135.04 ± 35.23
[1.25(OH)2D3] (pg/mL) 21.18 ± 7.37
IL-6 (pg/mL) 5.71 ± 3.80
OxLDL (U/L) 39.91 ± 19.55
α-Klotho (pg/mL) 331.10 ± 171.06
HOMA-IR 1.84 ± 1.67
HbA1c 7.8 ± 2.0
Table 2  Simple linear regression analysis between Klotho and other 
parameters in diabetic patients with CKD












Table 3  Multivariate linear regression analysis between Klotho and 
other parameters in diabetic patients with CKD
Variable Coefficient SE p value
Age 0.222 1.599 0.890
eGFR 0.090 0.626 0.886
Phosphorus 11.909 21.277 0.577
Calcium 2.424 10.701 0.821
PTH −0.291 0.253 0.252
ACR −0.636 0.105 0.036
HOMA-IR −0.322 0.588 0.018
IL-6 −7.889 6.098 0.199
FGF-23 −0.668 0.135 <0.001
Vit.D 8.465 3.225 0.010
OxLDL 1.856 1.223 0.132
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(p < 0.001), revealing a sound discriminant capacity of 
the model. The estimates obtained showed that group 1 
(<268) compared with group 3 (>440) had greater odds 
of ACR ≥181 (ORa = 1.324, p = 0.024) and that higher 
levels of vitamin D were statistically associated with 
lower values of ACR (ORa = 0.808, p < 0.001) (Table 4).
No statistical significant difference was found between 
groups 2 and 3, but the HOMA-IR obtained showed 
that group 1 (<268) had greater odds of HOMA-IR ≥2 
(ORa = 21.59, p = 0.017) when compared with group 3 
(>440). The area under the ROC curve for this optimized 
model was 0.978 (p < 0.001), revealing an excellent discri-
minant capacity of the model (Table 5).
Discussion
In the last few years, Klotho has become an inelucta-
ble topic of discussion among nephrologists, due to its 
known contribution to mineral metabolism homeostasis 
in general and phosphate handling in particular. For this 
reason, Klotho has been recurrently seen as a promising 
target for the management and treatment of patients with 
CKD. Nevertheless, contradictory recent evidence has 
raised questions on whether Klotho actually plays any 
active role in CKD.
CKD is a well-known multifactorial disease, with sev-
eral contributing factors and associated triggering agents. 
Most of these seem to be linked in a well-arranged web, 
and a single deregulation is able to affect the whole chain, 
producing different pathological outcomes. The addition 
of other comorbidities such as diabetes often leads to an 
extreme complex puzzle of interconnections which may 
be difficult to understand.
The current study investigated the correlations 
between serum Klotho levels and ACR and insulin resist-
ance, in type 2 diabetic patients with stage 2–3 CKD.
Results showed that Klotho levels were correlated with 
FGF23, vitamin D and insulin resistance, suggesting that 
Klotho levels might be affected by renal function. This 
seems to be in accordance with most of the studies that 
describe CKD as a state of FGF-23 resistance caused by 
the deficiency of Klotho [16]. Nevertheless, this is still a 
debatable subject, as conflicting results have reported that 
Klotho levels were significantly correlated with age, but 
not with eGFR or other parameters of mineral metabo-
lism in patients with CKD [8].
Table 4  GLM for the albumin-to-creatinine ratio (≥181)
GLM generalized linear model, ORa adjusted odds ratio, 95% CI for OR 95% confidence interval for the odds ratio, Ref category versus the one 
is making comparisons
Initial model Optimized model
ORa 95% CI for  ORa p value ORa 95% CI for  ORa p value
Klotho groups
<268 3.429 1.288–9.125 0.014 1.324 1.061–1.721 0.024
268–440 0.839 0.302–2.328 0.736 0.586 0.182–1.886 0.370
>440 Ref. Ref.
Vitamin D – – – 0.808 0.725–0.901 <0.001
p value (model) 0.007 <0.001
Area under ROC (p value) – 0.772 (p < 0.001)
Table 5  GLM for the HOMA-IR (≥2)
GLM generalized linear model, ORa adjusted odds ratio, 95% CI for OR 95% confidence interval for the odds ratio, Ref category versus the one 
is making comparisons
Initial model Optimized model
ORa 95% CI for  ORa p value ORa 95% CI for  ORa p value
Klotho groups
<268 30.000 8.256–109.006 <0.001 21.590 1.733–268.903 0.017
268–440 2.640 0.809–8.616 0.108 7.264 0.847–62.332 0.071
>440 Ref. Ref.
p value (model) <0.001 <0.001
Area under ROC (p value) 0.978 (p < 0.001)
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In this study, Klotho levels were associated with insulin 
resistance inasmuch as being a predictive factor for insulin 
resistance, as indicated by the optimized generalized model 
(Table 5). The association between Klotho levels and insu-
lin resistance also seems to be in accordance with other 
studies [9, 10]. These studies reported that Klotho levels 
can mediate insulin metabolism through the inhibition of 
tyrosine phosphorylation of insulin and IGF1 receptors, as 
well as enhancing glucose-induced insulin secretion via up-
regulating membrane retention of TRPV2. If the apparent 
Klotho deficiency seen in CKD stages is taken into consid-
eration, we might hypothesize that low Klotho levels could 
result in excessive insulin release, leading to a state of insu-
lin resistance.
When our variables were transferred to the multiple 
regression model, the link between Klotho and eGFR was 
lost. Klotho was mainly associated with ACR. In the gen-
eralized linear model, used to investigate the relationship 
of possible predictors, only Klotho was a predictive fac-
tor in the determination of the album-to-creatinine event 
(Table 4). This association seems, once again, to be in line 
with other recent studies. These have hypothesized and 
investigated direct and indirect mechanisms that could pos-
sibly explain how these two variables influence each other. 
On a direct level, it has been argued that interstitial inflam-
mation induced by proteinuria may downregulate Klotho 
expression. According to Moreno et al. [11], the release 
of inflammatory cytokines such as tumor necrosis fac-
tor (TNF)-like weak inducer of apoptosis’ (TWEAK) and 
TNF-α was responsible for the downregulation of Klotho 
expression through a nuclear factor kappa-B-dependent 
mechanism. This seems to be a valid hypothesis to support 
the correlation between Klotho levels and ACR found in 
our study. The observations from Moreno et al. were sup-
ported by another study that reported an increased Klotho 
circulating level in type 2 diabetic patients whose protein-
uria was ameliorated with losartan [12]. According to the 
authors, the use of renin-angiotensin system antagonists 
with angiotensin-converting enzyme inhibitors or angioten-
sin receptor blockers in patients with diabetic nephropathy 
was able to reverse Klotho’s downregulation induced by 
angiotensin II, therefore retarding disease progression.
Another direct mechanism thought to be part of the 
relationship Klotho/ACR is the one involving the vascular 
endothelial growth factor A (VEGF-A). It is believed that 
VEGF-A plays a pathogenic role in diabetic nephropathy, 
particularly on angiogenesis and vascular permeability. In 
their study on diabetic patients, Kacso and colleagues [17] 
observed a consistent positive relationship between soluble 
Klotho and VEGF-A (both factors having low levels in the 
presence of microalbuminuria). It is still to be understood 
whether they both respond to the same pathogenic trigger 
or whether it is a reactive action to the other. Nevertheless, 
we may hypothesize that the downregulation Klotho/
VEGF-A can lead to ACR worsening through their impact 
on endothelial dysfunction.
In addition to these mechanisms, Klotho has also an 
endogenous anti-fibrotic function via antagonism of Wnt/β-
catenin signaling, which promotes fibrinogenesis. There-
fore, it is reasonable to argue that a loss of Klotho may be 
associated with the progression of diabetic nephropathy 
and ACR worsening by accelerated fibrinogenesis [18, 19].
Some studies have also speculated that the correlation 
between Klotho and ACR may be due to indirect mecha-
nisms as well. Within the Klotho/FGF-23/vitamin D axis, 
it is already known that low Klotho levels are associated 
with increased FGF-23 and decreased vitamin D levels. 
FGF-23 is then able to indirectly increase proteinuria by 
diminishing calcitriol synthesis [20] and inducing endothe-
lium dysfunction [21]. It is also negatively correlated with 
vitamin D levels in diabetic nephropathy patients with 
microalbuminuria [22, 23]. Thus, it is not unreasonable 
to hypothesize that Klotho and ACR levels might be cor-
related through indirect, albeit unclear but possibly FGF-
23-mediated, mechanisms.
Despite some limitations, namely the small size of the 
sample and the limited statistical power of the applied, this 
study offers an added value by generating hypotheses. Not-
withstanding this, further studies are needed to determine 
the degree of correlation between plasma levels of soluble 
Klotho and ACR.
Conclusions
The current study found that Klotho levels were influenced 
by FGF-23, vitamin D and insulin resistance, variables that 
are affected by the renal function. Despite this, the eGFR 
lost its relationship with Klotho in the multiple regression 
model. The generalized linear model revealed that Klotho 
was the sole predictive factor in the determination of the 
album-to-creatinine event and insulin resistance. Addi-
tional studies are required in clarifying the meaning of 
the relationship between Klotho and ACR, and the links 
between Klotho and insulin resistance also demands further 
analysis.
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